Similar articles

• Questionable relation of aryl hydrocarbon hydroxylase to lung-cancer risk.

  Paigen B, Gurtoo HL, Minowada J, Houten L, Vincent R, Paigen K, Parker NB, Ward E, Hayner NT. Paigen B, et al. N Engl J Med. 1977 Aug 18;297(7):346-50. doi: 10.1056/NEJM197708182970702. N Engl J Med. 1977. PMID: 876325
• Cancer susceptibility and carcinogen metabolism.

  Gelboin HV. Gelboin HV. N Engl J Med. 1977 Aug 18;297(7):384-6. doi: 10.1056/NEJM197708182970709. N Engl J Med. 1977. PMID: 876330 No abstract available.
• Aryl hydrocarbon hydroxylase activity in pulmonary macrophages and lymphocytes from lung cancer and noncancer patients.

  McLemore TL, Martin RR, Busbee DL, Richie RC, Springer RR, Toppell KL, Cantrell ET. McLemore TL, et al. Cancer Res. 1977 Apr;37(4):1175-81. Cancer Res. 1977. PMID: 844043 No abstract available.
• Better perspectives on use of biological markers in monitoring of lung cancer risk in occupational settings.

  Jedrychowski W, Maugeri U, Bianchi I. Jedrychowski W, et al. G Ital Med Lav. 1993 Sep-Nov;15(5-6):99-104. G Ital Med Lav. 1993. PMID: 7615181 Review.
• [The strategic use of genetic polymorphisms in carcinogen metabolizing enzyme for prevention of cancer].

  Ikawa S. Ikawa S. Gan To Kagaku Ryoho. 1997 Feb;24(4):454-9. Gan To Kagaku Ryoho. 1997. PMID: 9063483 Review. Japanese.